#phase 3
3 stories
AriBio Phase 3 Results for Alzheimer's Drug
AriBio's Alzheimer's drug AR1001 nears phase 3 results with Fosun Pharmaceuticals.
Seekingalpha · 1m
Latigo Stock May Profit From Vertex Market
Latigo Biotherapeutics (LTGO) could see significant gains as Vertex's market groundwork supports its onzotrigine trials.
Seekingalpha · 1m
Geron Targets $240M RYTELO Revenue by 2026
Geron expects $230-240 million in 2026 RYTELO revenue as community adoption grows
Yahoo Finance · 1m